Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of MBX-2044 to Evaluate the Multiple-dose Pharmacokinetics, Safety and Tolerability When Administered Orally in Patients With Type 2 Diabetes
Phase of Trial: Phase II
Latest Information Update: 07 May 2015
At a glance
- Drugs MBX 2044 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors CymaBay Therapeutics
- 17 Sep 2007 Status changed from recruiting to completed.
- 08 Jan 2007 New trial record.